INS and obesity due to melanocortin 4 receptor deficiency: Treatment-insulin interactions were suggestive for overall and obesity-related cancers (adjusted interaction p = 0.055 and 0.072, respectively), but no evidence of interaction was observed for non-obesity-related cancers (adjusted interaction p = 0.469).